Journal
TRANSFUSION CLINIQUE ET BIOLOGIQUE
Volume 9, Issue 1, Pages 15-22Publisher
EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/S1246-7820(01)00210-5
Keywords
blood group antigen; immunoglobulin gene; monoclonal antibody; phage display; Rh immune globulin
Categories
Funding
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054516, R01HL061844] Funding Source: NIH RePORTER
- NHLBI NIH HHS [P50-HL54516, R01 HL61844] Funding Source: Medline
Ask authors/readers for more resources
With the development of murine hybridoma technology over a quarter century ago, the ability to produce large quantifies of well-characterized monoclonal antibody preparations revolutionized diagnostic and therapeutic medicine. For many applications in transfusion medicine, however, the production of serological reagents in mice has certain biological limitations relating to the difficulty in obtaining murine monoclonal antibodies specific for many human blood group antigens. Furthermore, for therapeutic purposes, the efficacy of murine-derived immunoglobulin preparations is limited by the induction of anti-mouse immune responses. Technical difficulties inherent in human hybridoma formation have led to novel molecular approaches that facilitate the isolation and production of human antibodies without the need for B-cell transformation, tissue culture, or even immunized individuals. These technologies, referred to as 'repertoire cloning' or 'Fab/phage display', involve the rapid cloning of immunoglobulin gene segments to create immune libraries from which antibodies with desired specificities can be selected. The use of such recombinant methods in transfusion medicine is anticipated to play an important role in the development and production of renewable supplies of low-cost reagents for diagnostic and therapeutic applications. (C) 2002 Editions scientifiques et medicales Elsevier SAS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available